The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma

Infectious Agents and Cancer

Volumn 9, Issue 1, 2014, Pages

  Ambrosio, Maria Raffaella ^a   Navari, Mohsen ^a   Di Lisio, Lorena ^b   Leon, Eduardo Andres ^c   Onnis, Anna ^a   Gazaneo, Sara ^a   Mundo, Lucia ^a   Ulivieri, Cristina ^a   Gomez, Gonzalo ^b   Lazzi, Stefano ^a   Piris, Miguel Angel ^b   Leoncini, Lorenzo ^a   De Falco, Giulia ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Burkitt lymphoma; EBV; MicroRNAs

Indexed keywords

INTERLEUKIN 6 RECEPTOR ALPHA; MICRORNA; MICRORNA 142 5P; MICRORNA 181; MICRORNA 197; MICRORNA 501; MICRORNA 510; MICRORNA 574; MICRORNA 609; MICRORNA 7; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ARTICLE; BIOINFORMATICS; BURKITT LYMPHOMA; CELL FUNCTION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE ONTOLOGY; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION STUDY;

EID: 84899931764     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-9-12     Document Type: Article

References (47)

1. A sarcoma involving the jaws in African children. Burkitt DP, Br J Surg 1958 46 218 10.1002/bjs.18004619704 13628987
2. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Magrath I, Br J Haematol 2012 156 744 756 10.1111/j.1365-2141.2011.09013.x 22260300
3. Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. Epstein MA, Barr YM, Lancet 1964 1 252 3 14090852
4. Human c-myc oncgene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Croce CM, Proc Natl Acad Sci U S A 1982 79 7824 7827 10.1073/pnas.79.24.7824 6961453
5. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Taub R, Kirsch I, Morton C, Lenoir G, Aaronson S, Leder P, Proc Natl Acad Sci U S A 1982 79 7837 7841 10.1073/pnas.79.24.7837 6818551
6. Burkitt lymphoma. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC Press, International Agency for Research on Cancer, 4 2008 262 264
7. The genetic landscape of mutations in Burkitt lymphoma. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, et al. Nat Genet 2012 44 1321 1325 10.1038/ng.2468 23143597
8. Molecular diagnosis of Burkitt's lymphoma. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, et al. N Engl J Med 2006 354 2431 2442 10.1056/NEJMoa055759 16760443
9. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, et al. N Engl J Med 2006 354 2419 2430 10.1056/NEJMoa055351 16760442
10. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Piccaluga PP, De Falco G, Kustagi M, Gazzola A, Agostinelli C, Tripodo C, Leucci E, Onnis A, Astolfi A, Sapienza MR, Bellan C, Lazzi S, Tumwine L, Mawanda M, Ogwang M, Calbi V, Formica S, Califano A, Pileri SA, Leoncini L, Blood 2011 117 3596 3608 10.1182/blood-2010-08-301556 21245480
11. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, De Falco G, Githanga J, Horn H, Nyagol J, Ott G, Palatini J, Pfreundschuh M, Rogena E, Rosenwald A, Siebert R, Croce CM, Stein H, Leukemia 2011 25 1869 1876 10.1038/leu.2011.156 21701491
12. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. Onnis A, Navari M, Antonicelli G, Morettini F, Mannucci S, De Falco G, Vigorito E, Leoncini L, Blood Cancer J 2012 2 84 10.1038/bcj.2012.29 22941339
13. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. Cai X, Schäfer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR, PLoS Pathog 2006 3 23
14. A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, Middeldorp J, Shapiro M, Thorley-Lawson DA, PLoS Pathog 2011 7 1002193 10.1371/journal.ppat. 1002193 21901094
15. Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. Nourse JP, Crooks P, Keane C, Nguyen-Van D, Mujaj S, Ross N, Jones K, Vari F, Han E, Trappe R, Fink S, Gandhi MK, J Virol Methods 2012 184 46 54 10.1016/j.jviromet.2012.05.005 22609801
16. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas. Ramakrishnan R, Donahue H, Garcia D, Tan J, Shimizu N, Rice AP, Ling PD, PLoS One 2011 6 27271 10.1371/journal.pone.0027271 22102884
17. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Leucci E, Onnis A, Cocco M, De Falco G, Imperatore F, Giuseppina A, Costanzo V, Cerino G, Mannucci S, Cantisani R, Nyagol J, Mwanda W, Iriso R, Owang M, Schurfeld K, Bellan C, Lazzi S, Leoncini L, Int J Cancer 2010 126 1316 1326 19530237
18. Role of EBV in microRNA dysregulation in burkitt lymphoma. De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L, Semin Cancer Biol 2009 19 401 416 10.1016/j.semcancer.2009.07.003 19619656
19. Alteration of microRNAs regulated by c-Myc in burkitt lymphoma. Onnis A, De Falco G, Antonicelli G, Onorati M, Bellan C, Sherman O, Sayed S, Leoncini L, PLoS One 2010 5 1 9
20. Infectious agents and lymphoma. De Falco G, Rogena EA, Leoncini L, Semin Diagn Pathol 2011 28 178 187 10.1053/j.semdp.2011.01.003 21842703
21. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML, J Mol Diagn 2004 6 378 85 10.1016/S1525-1578(10)60535-1 15507678
22. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. Ach RA, Wang H, Curry B, BMC Biotechnol 2008 8 69 10.1186/1472-6750-8-69 18783629
23. Approximate p-values for local sequence alignments: numerical studies. Storey JD, Siegmund D, J Comput Biol 2001 8 549 556 10.1089/106652701753216530 11694182
24. TarBase: a comprehensive database of experimentally supported animal microRNA targets. Sethupathy P, Corda B, Hatzigeorgiou AG, RNA 2006 12 192 197 16373484
25. A uniform system for microRNA annotation. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T, RNA 2003 9 277 279 10.1261/rna.2183803 12592000
26. A literature network of human genes for high-throughput analysis of gene expression. Jenssen TK, Laegreid A, Komorowski J, Hovig E, Nat Genet 2001 28 21 28 11326270
27. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609
28. The alteration of lipid metabolism in burkitt lymphoma identifies a novel marker: adipophilin. Ambrosio MR, Piccaluga PP, Ponzoni M, Rocca BJ, Malagnino V, Onorati M, De Falco G, Calbi V, Ogwang M, Naresh KN, Pileri SA, Doglioni C, Leoncini L, Lazzi S, PLoS ONE 2012 7 44315 10.1371/journal.pone.0044315 22952953
29. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Herreman A, Dierickx D, Morscio J, Camps J, Bittoun E, Verhoef G, De Wolf-Peeters C, Sagaert X, Tousseyn T, Leuk Lymphoma 2013 54 2190 2199 10.3109/10428194.2013.775436 23402267
30. A20 (TNFAIP3) deletion in Epstein-Barr virus- associatedlymphoproliferative disorders/lymphomas. Ando M, Sato Y, Takata K, Nomoto J, Nakamura S, Ohshima K, Takeuchi T, Orita Y, Kobayashi Y, Yoshino T, PLoS One 2013 8 56741 10.1371/journal.pone.0056741 23418597
31. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I, De Wolf-Peeters C, Sagaert X, Tousseyn T, Am J Transplant 2013 13 1305 1316 10.1111/ajt.12196 23489474
32. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. Chung GT, Lou WP, Chow C, To KF, Choy KW, Leung AW, Tong CY, Yuen JW, Ko CW, Yip TT, Busson P, Lo KW, J Pathol 2013 231 311 322 23868181
33. Identification of a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma. Chung GT, Lung RW, Hui AB, Hui AB, Yip KY, Woo JK, Chow C, Tong CY, Lee SD, Yuen JW, Lun SW, Tso KK, Wong N, Tsao SW, Yip TT, Busson P, Kim H, Seo JS, O'Sullivan B, Liu FF, To KF, Lo KW, J Pathol 2013 231 158 67 10.1002/path.4240 23878065
34. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Bornkamm GW, Int J Cancer 2009 124 1745 1755 10.1002/ijc.24223 19165855
35. Epstein-Barr virus-mediated dysregulation of human microRNA expression. Godshalk SE, Bhaduri-McIntosh S, Slack FJ, Cell Cycle 2008 7 3595 3600 10.4161/cc.7.22.7120 19001862
36. The microRNAs of Epstein-Barr virus are expressed at dramatically differing levels among cell lines. Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B, Virology 2009 386 387 397 10.1016/j.virol.2009.01.006 19217135
37. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. Lo AK, Dawson CW, Jin DY, Lo KW, J Pathol 2012 227 392 403 10.1002/path.4025 22431062
38. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma. Shaw Shah KM, Young LS, Clin Microbiol Infect 2009 15 982 988 10.1111/j.1469-0691. 2009.03033.x 19874382
39. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, Pappas K, Yu JS, Hodakoski C, Mense S, Klein J, Pegno S, Sulis ML, Goldstein H, Amendolara B, Lei L, Maurer M, Bruce J, Canoll P, Hibshoosh H, Parsons R, Science 2013 341 399 402 10.1126/science.1234907 23744781
40. Targeting the PI3K/AKT/mTOR pathway. Owonikoko TK, Khuri FR, Am Soc Clin Oncol Educ Book 2013 395 401
41. Interleukin-6: from basic science to medicine-40 years in immunology. Kishimoto T, Annu Rev Immunol 2005 23 1 21 10.1146/annurev.immunol.23.021704. 115806 15771564
42. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Büschenfelde KH M z, Rose-John S, J Exp Med 1996 183 1399 1406 10.1084/jem.183.4.1399 8666898
43. Down-regulation of gp130 in nasopharyngeal carcinoma. Lin YS, Lin LC, Huang MH, Huang YT, Am J Rhinol Allergy 2009 23 28 32 10.2500/ajra.2009.23.3257 19379608
44. Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. Amoroso R, Fitzsimmons L, Thomas WA, Kelly GL, Rowe M, Bell AL, J Virol 2011 85 996 1010 10.1128/JVI.01528-10 21068248
45. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R, PLoS Pathog 2012 8 1002704 10.1371/journal.ppat. 1002704 22615564
46. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, Salto-Tellez M, Chng WJ, J Pathol 2011 223 496 510 10.1002/path.2823 21294123
47. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al-Dayel F, Hussain AR, Al-Kuraya KS, J Pathol 2011 224 355 366 10.1002/path.2864 21506127